Walker on Progress
Deconstructing the future of how we build, innovate, and grow.
About This Column
Patrick Walker is a strategist and writer fascinated by the "how" and "why" of modern advancement. After years of analyzing the intricate value chains and regulatory hurdles of the biopharmaceutical world, Patrick now applies his forensic curiosity to the broader landscape of innovation. From breakthroughs in manufacturing and AI to the quiet shifts in global sustainability, he examines the forces reshaping our industries and our daily lives. Patrick’s column is built for the curious professional, offering a unique perspective on how small technological shifts create massive market ripples.
Walker dissects key partnerships, regulatory changes, sustainability initiatives, and company performance – highlighting the implications for market competition and future growth. He offers a unique perspective on how innovation in areas like AI, drug delivery, and manufacturing is impacting the entire value chain. Readers can expect insightful analysis of industry news, company recognitions, and market reports, all geared towards understanding the forces reshaping the pharmaceutical landscape and identifying opportunities for strategic advantage.
Displaying items 61-80 of 733 in total
Hootsuite's AI Gambit: Can 'Wisdom' Redefine Social Intelligence?
Echo IQ's Power Play: Strategic Hires Target U.S. Market Dominance
The Autonomous SMB: Workiz's AI Engine Aims to Automate Field Service Growth
Oracle and Theator Bring AI Eyes into the Operating Room
Netgain's New AI Engine Aims to End Accounting's Spreadsheet Nightmare
The CFO Paradox: Boardroom Optimism Soars Amidst Economic Doubt
The AI Confessional: Bots Unlock the Truth B2B Buyers Won't Tell You
United's Aerial Arena: How Starlink is Fueling a New Era of Inflight TV
DAYLY's Wellness Gambit: Can Vitamin-Infused Toothpaste Remake a Daily Ritual?
Beyond the Pill: Lilly and ŌURA Bet on Data for GLP-1 Market Dominance
RBC's Power Play: Inside the Strategic Bet on the Vancouver Canucks
Schwab's Decade on The Civic 50: A Blueprint for Corporate Impact
Hollywood's New Money: Veterans Reshape Film Finance with Data, Not Drama
The Operational Architect: Headwater Science Taps Barnes to Scale Evidence
Contango’s Three-Front Gambit: Juggling Drills, Dollars, and Dissent
Remora's New Platform Gives Options Traders an AI Co-Pilot
Elevar's Big Bet: A Single Drug to Fight Cancers by Gene, Not by Type
Cover Whale's Gambit: From Niche MGA to Transportation Risk Powerhouse
Denim, Decibels, and Dollars: Wrangler's Country Music Masterstroke
